Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study.
作者： Hanneke W M van Laarhoven , Camiel Rosman , Rachel S van der Post , Maarten C C M Hulshof , Leonie R van der Werf
DOI: 10.1080/0284186X.2020.1870246
关键词:
摘要: Background With increasing interest in organ-preserving strategies for potentially curable esophageal cancer, real-world data is needed to understand the impact of pathological tumor response after neoadjuvant chemoradiotherapy (CRT) on patient outcome. The objective this study assess association between following CROSS CRT and long-term overall survival (OS) a nationwide cohort. Material methods All patients diagnosed Netherlands with cancer 2009 2017, treated followed by esophagectomy were included. Through record linkage Dutch Pathology Registry (PALGA), obtained. primary outcome was based ypTNM, classified into complete (ypT0N0) incomplete responders (ypT0N+, ypT+N0, ypT+N+). Multivariable logistic Cox regression models used identify predictors (pCR) survival. Results A total 4946 Overall, 24% achieved pCR, 19% adenocarcinoma 42% squamous cell carcinoma. Patients pCR had better estimated 5-year OS compared (62% vs. 38%, p Conclusion In population-based study, ypTNM-stage associated different prognostic subgroups. quarter ypT0N0 favorable survival, while one-third an ypT+N+ very poor could help more accurate assessments individual prognosis treatment decisions.
sci-hub.st 参考文章(42)
Joel Shapiro, J Jan B van Lanschot, Maarten C C M Hulshof, Pieter van Hagen, Mark I van Berge Henegouwen, Bas P L Wijnhoven, Hanneke W M van Laarhoven, Grard A P Nieuwenhuijzen, Geke A P Hospers, Johannes J Bonenkamp, Miguel A Cuesta, Reinoud J B Blaisse, Olivier R C Busch, Fiebo J W ten Kate, Geert-Jan M Creemers, Cornelis J A Punt, John Th M Plukker, Henk M W Verheul, Ernst J Spillenaar Bilgen, Herman van Dekken, Maurice J C van der Sangen, Tom Rozema, Katharina Biermann, Jannet C Beukema, Anna H M Piet, Caroline M van Rij, Janny G Reinders, Hugo W Tilanus, Ewout W Steyerberg, Ate van der Gaast, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial The Lancet Oncology. ,vol. 16, pp. 1090- 1098 ,(2015) , 10.1016/S1470-2045(15)00040-6
P.A.M. Heeren, W. Kelder, I. Blondeel, H.L. van Westreenen, H. Hollema, J.Th. Plukker, Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Ejso. ,vol. 31, pp. 270- 276 ,(2005) , 10.1016/J.EJSO.2004.12.001
S. Komukai, T. Nishimaki, T. Suzuki, T. Kanda, S. Kuwabara, K. Hatakeyama, Significance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. British Journal of Surgery. ,vol. 89, pp. 213- 219 ,(2002) , 10.1046/J.1365-2168.2002.01981.X
Andrew P Barbour, Mark Jones, Mithat Gonen, David C Gotley, Janine Thomas, Damien B Thomson, Bryan Burmeister, B Mark Smithers, None, Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response Annals of Surgical Oncology. ,vol. 15, pp. 2894- 2902 ,(2008) , 10.1245/S10434-008-0084-Y
Jakob Robert Izbicki, Stefan Benedikt Hosch, Uwe Pichlmeier, Alexander Rehders, Christoph Busch, Axel Niendorf, Bernward Passlick, Christoph Erich Broelsch, Klaus Pantel, Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer The New England Journal of Medicine. ,vol. 337, pp. 1188- 1194 ,(1997) , 10.1056/NEJM199710233371702
Knut Nygaard, Steinar Hagen, Hanne Sand Hansen, Reidulv Hatlevoll, Ragnar Hultborn, Anders Jakobsen, Matti Mäntyla, Hans Modig, Eva Munck-Wikland, Bengt Rosengren, Johan Tausjø, Kjell Elgen, Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World Journal of Surgery. ,vol. 16, pp. 1104- 1110 ,(1992) , 10.1007/BF02067069
Enrique Vazquez–Sequeiros, Linan Wang, Lawrence Burgart, William Harmsen, Alan Zinsmeister, Mark Allen, Mary Jondal, Maurits Wiersema, Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. ,vol. 122, pp. 1815- 1821 ,(2002) , 10.1053/GAST.2002.33665
Eva Karamitopoulou, Svenja Thies, Inti Zlobec, Katja Ott, Marcus Feith, Julia Slotta-Huspenina, Florian Lordick, Karen Becker, Rupert Langer, Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. The American Journal of Surgical Pathology. ,vol. 38, pp. 1551- 1556 ,(2014) , 10.1097/PAS.0000000000000255
Daniel King Hung Tong, Simon Law, Dora Lai Wan Kwong, Kwok Wah Chan, Alfred King Yin Lam, Kam Ho Wong, Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Annals of Surgical Oncology. ,vol. 17, pp. 2184- 2192 ,(2010) , 10.1245/S10434-010-0995-2
Viren R. Patel, Wayne L. Hofstetter, Arlene M. Correa, Atin Agarwal, Asif Rashid, Manoop S. Bhutani, Steven H. Lin, Jaffer A. Ajani, Stephen G. Swisher, Dipen M. Maru, Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. The Annals of Thoracic Surgery. ,vol. 98, pp. 1064- 1071 ,(2014) , 10.1016/J.ATHORACSUR.2014.04.099